Rep. Marjorie Taylor Greene Buys Amgen Inc. (NASDAQ:AMGN) Stock

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on September 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on September 11th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of iShares Bitcoin Trust ETF (NASDAQ:IBIT) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of Morgan Stanley (NYSE:MS) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of Duke Energy (NYSE:DUK) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of ASML (NASDAQ:ASML) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of CrowdStrike (NASDAQ:CRWD) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of Digital Realty Trust (NYSE:DLR) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of Morgan Stanley (NYSE:MS) on 8/28/2025.

Amgen Stock Performance

NASDAQ:AMGN opened at $273.97 on Tuesday. The stock has a 50-day simple moving average of $288.42 and a two-hundred day simple moving average of $288.61. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $335.88. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The firm has a market capitalization of $147.49 billion, a PE ratio of 22.40, a P/E/G ratio of 2.37 and a beta of 0.49.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same period in the previous year, the business earned $4.97 earnings per share. The business’s revenue was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.5%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s payout ratio is currently 77.84%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on AMGN. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Citigroup boosted their price objective on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a research report on Wednesday, September 24th. UBS Group lowered their price objective on Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Raymond James Financial began coverage on Amgen in a research report on Wednesday, September 3rd. They issued a “market perform” rating on the stock. Finally, Morgan Stanley boosted their price objective on Amgen from $330.00 to $333.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and an average price target of $309.70.

Institutional Investors Weigh In On Amgen

Hedge funds have recently made changes to their positions in the company. Brighton Jones LLC increased its stake in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares during the last quarter. 111 Capital bought a new stake in Amgen during the fourth quarter worth approximately $411,000. MassMutual Private Wealth & Trust FSB increased its stake in Amgen by 6.5% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 6,549 shares of the medical research company’s stock worth $2,040,000 after acquiring an additional 400 shares during the last quarter. Versant Capital Management Inc increased its stake in Amgen by 48.6% during the first quarter. Versant Capital Management Inc now owns 1,817 shares of the medical research company’s stock worth $566,000 after acquiring an additional 594 shares during the last quarter. Finally, Legacy Private Trust Co. increased its stake in Amgen by 7.9% during the first quarter. Legacy Private Trust Co. now owns 8,322 shares of the medical research company’s stock worth $2,593,000 after acquiring an additional 606 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the transaction, the senior vice president owned 7,209 shares of the company’s stock, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.69% of the stock is owned by insiders.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2026 election.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.